Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsis

Transfusion Medicine Reviews

Volumn 16, Issue 1, 2002, Pages 11-24

  Parravicini, Elvira ^a   Ven, Carmella Van De ^a   Anderson, Lauren ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; STEM CELL FACTOR;

ARTICLE; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MORTALITY; NEWBORN; NEWBORN SEPSIS; PROPHYLAXIS;

EID: 0036144227     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2002.29348     Document Type: Article

References (68)

1. Neonatal sepsis
2. Sepsis syndrome and septic shock in pediatrics: Current concepts of terminology, pathophysiology and management
3. Neonatal Sepsis. Progress in diagnosis and management
4. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale
5. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis
6. Early-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network
7. Late-onset sepsis in very low birthweight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network
8. Immunoglobulin supplementation in prevention or treatment of neonatal sepsis
9. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis
10. Intravenous gamma globulin as adjunct therapy for severe group B streptococcal disease in the newborn
11. Intravenous immunoglobulin therapy for early-onset sepsis in premature neonates
12. A controlled trial of prophylactic intravenous immunoglobulin (IVIG) to reduce nosocomial infections in VLBW infants
13. Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants
14. Intravenous gamma globulin therapy for prophylaxis of infection in high-risk neonates
15. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot study
16. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates
17. Polymorphonuclear leukocyte transfusion for the treatment of sepsis in the newborn infant
18. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature neutrophils
19. Role of circulating complement and polymorphonuclear leukocyte transfusion in treatment and outcome in critically ill neonates with sepsis
20. Buffy coat transfusions in neutropenic neonates with presumed sepsis. A prospective randomized trial
21. Buffy coat transfusions in neonates with sepsis and neutrophil storage pool depletion
22. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor
23. Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia
24. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors
25. Decreased G-CSF and IL- 3 production and gene expression from mononuclear cells of newborn infants
26. Circulating steel factor (SLF) and G-CSF levels in preterm and term newborn and adult peripheral blood
27. Recombinant human granulocyte-macrophage colony stimulating factor primes neonatal granulocytes for enhanced oxidative metabolism and chemotaxis
28. Modulation of neonatal myelopoiesis in newborn rats following 7-day administration of either GM-CSF or IL-3 (granulocyte-monocyte colony stimulating factor or interleukin-3)
29. Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions
30. Decreased stimulated GM-CSF production and GM-CSF gene expression but normal numbers of GM-CSF receptors in human term newborns compared to adults
31. Increased granulocyte-macrophage colony- stimulating factor mRNA instability in cord versus adult mononuclear cells is translation-dependent and associated with increased levels of A + U-rich element binding factor
32. Decreased macrophage colony-stimulating factor mRNA expression from activated cord versus adult mononuclear cells: Altered post transcriptional stability
33. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells
34. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells
35. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34 + lin- cells, and the generation of colony-forming cell progeny from CD34 + lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor
36. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential
37. Effect of stem cell factor with and without granulocyte colony-stimulating factor on neonatal hematopiesis: In vivo induction of newborn myelopoiesis and reduction of mortality during experimental group B streptococcal sepsis
38. Coordinate regulation of Steel factor, its receptor (Kit) and cytoadhesion molecule (ICAM-1 and ELAM-1) mRNA expression in human vascular endothelial cells of differing origins
39. Transforming growth factor-β1, macrophage inflammatory protein-lα, and interleukin-8 gene expression is lower in stimulated human neonatal compared to adult mononuclear cells
40. Seven-day administration of recombinant human granulocyte colony-stimulating factor to newborn rats: Modulation of neonatal neutrophilia, myelopoiesis, and group B streptococcus sepsis
41. Modulation of neonatal rat myeloid kinetics resulting in peripheral neutrophilia by single pulse administration of rh granulocyte-macrophage colony-stimulating factor and rh granulocyte colony-stimulating factor
42. Sequential administration of interleukin-6 and granulocyte colony-stimulating factor in newborn rats: Modulation of newborn granulopoiesis and thrombopoiesis
43. Effect of interleukin-11 with and without granulocyte colony-stimulating factor on in vivo neonatal rat hematopoiesis: Induction of neonatal thrombocytosis by interleukin-11 and synergistic enhancement of neurrophilia by Interleukin-11 + granulocyte colony-stimulating factor
44. The combined effects of interleukin-11, stem cell factor, and granulocyte colony-stimulating factor on newborn rat hematopoiesis: Significant enhancement of the absolute neutrophil count
45. Blood and marrow neutrophils during experimental group B streptococcal infection: Quantification of the stem cell, proliferative, storage and circulating pools
46. Prophylactic or simultaneous administration of recombinant human granulocyte colony stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats
47. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus
48. Therapeutic use of recombinant human granulocyte-macrophage colony-stimulating factor in neonatal rats with type III group B streptococcal sepsis
49. Endogenous inteleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats
50. Pre and post-natal development of granulocyte stem cells (CFUc) in the rat
51. Lymphokines: Enhancement by granulocyte-macrophage and granulocyte colony-stimulating factors of neonatal myeloid kinetics and functional activation of polymorphonuclear leukocytes
52. Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-met-Leu-Phe receptors
53. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils
54. Impaired surface membane expression of C 3bi but not C3b receptors on neonatal neutrophils
55. Abnormal stimulated adherence of neonatal granulocytes: Impaired induction of surface Mac-I by chemotactic factors or secretagogues
56. GM-CSF primes and modulates neonatal PMN motility: Up-regulation of C3bi (Mol) expression with alteration in PMN adherence and aggregation
57. Biological activities of human pluripotent hematopoietic colony-stimulating factor on normal and leukemic cells
58. Therapeutic efficacy of granulocyte colony-stimulation factor alone and in combination with antibiotics against Pseudomonas aeruginosa infections in mice
59. Study of the prophylactic and therapeutic effect of human granulocyte-colony stimulating factor (G-CSF) on experimental pyelonephritis induced by Pseudomonas aeruginase in neutropenic mice
60. Mechanism of protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on pseudomonas infection
61. A randomized, placebo-controlled trial of recombinant human granulocyte-colony stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia
62. Long term (2 years) hematologic, immunologic, and developmental follow-up of neonates with presumed sepsis treated with G-CSF during the first three days of life
63. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia
64. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis
65. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis
66. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: Significant induction of circulatory neutrophils, monocytes, platelets and bone marrow neutrophils
67. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates